Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$3.65 +1.1%	$3.96	$2.14 ▼ $6.82	$154.81M	1.23	87,989 shs	217,608 shs
IPSC Century Therapeutics	$0.58 -1.2%	$0.55	$0.34 ▼ $3.29	$50.14M	1.77	528,180 shs	694,634 shs
KRRO Korro Bio	$11.75 -4.9%	$14.58	$10.29 ▼ $98.00	$115.97M	2.45	110,322 shs	79,262 shs
NMRA Neumora Therapeutics	$0.75 -5.1%	$0.75	$0.61 ▼ $17.19	$127.08M	2.74	1.54 million shs	578,172 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	0.00%	-1.10%	-11.08%	-27.07%	+67.13%
IPSC Century Therapeutics	0.00%	+1.13%	+4.13%	-0.31%	-79.65%
KRRO Korro Bio	0.00%	-8.79%	-10.51%	-48.61%	-65.09%
NMRA Neumora Therapeutics	0.00%	-6.96%	+15.60%	-34.53%	-91.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DMAC DiaMedica Therapeutics	1.3283 of 5 stars	3.5	1.0	2.5	0.0	0.0
IPSC Century Therapeutics	2.2742 of 5 stars	3.5	4.0	0.0	1.7	0.6
KRRO Korro Bio	1.9368 of 5 stars	3.6	3.0	1.1	0.0	0.6
NMRA Neumora Therapeutics	1.5403 of 5 stars	3.1	0.0	0.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	119.18% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	630.43% Upside
KRRO Korro Bio	3.29	Buy	$102.43	771.73% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,144.73% Upside

Current Analyst Ratings Breakdown

Latest IPSC, KRRO, DMAC, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
4/16/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
IPSC Century Therapeutics	$6.59M	7.52	N/A	N/A	$1.90 per share	0.30
KRRO Korro Bio	$2.27M	48.60	N/A	N/A	$17.12 per share	0.69
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/6/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)

Latest IPSC, KRRO, DMAC, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
IPSC Century Therapeutics	N/A	11.70	11.70
KRRO Korro Bio	N/A	9.41	9.41
NMRA Neumora Therapeutics	N/A	8.98	8.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
IPSC Century Therapeutics	50.20%
KRRO Korro Bio	13.18%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	7.30%
IPSC Century Therapeutics	5.00%
KRRO Korro Bio	4.60%
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.75 million	Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable

IPSC, KRRO, DMAC, and NMRA Headlines

Recent News About These Companies

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts

June 1, 2025 | marketbeat.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 27, 2025 | globenewswire.com

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development

May 24, 2025 | uk.investing.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 14, 2025 | prnewswire.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

May 13, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

May 11, 2025 | finance.yahoo.com

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025 | globenewswire.com

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%

April 23, 2025 | aaii.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

April 16, 2025 | investing.com

Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating

April 9, 2025 | tipranks.com

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

April 8, 2025 | accessnewswire.com

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline

April 7, 2025 | accessnewswire.com

NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

April 7, 2025 | globenewswire.com

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

April 7, 2025 | globenewswire.com

NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 7, 2025 | accessnewswire.com

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 7, 2025 | businesswire.com

Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class Action - NMRA

April 7, 2025 | accessnewswire.com

FINAL REMINDER NMRA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Neumora Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit

April 7, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, KRRO, DMAC, and NMRA Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$3.65 +0.04 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 +0.00 (+0.14%)

As of 04:04 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Century Therapeutics NASDAQ:IPSC

$0.57 -0.01 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$0.56 -0.01 (-2.09%)

As of 07:24 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Korro Bio NASDAQ:KRRO

$11.75 -0.60 (-4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$12.38 +0.64 (+5.40%)

As of 06:51 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Neumora Therapeutics NASDAQ:NMRA

$0.75 -0.04 (-5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+1.21%)

As of 07:29 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time